Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab and Reduced Fluence-PDT for AMD
NCT00527475Phase 2Completed
- Sponsor
- Texas Retina Associates
- Start
- May 2007
- Primary completion
- Jan 2010
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of verteporfin in Age-related macular degeneration (AMD), sponsored by Texas Retina Associates. Started May 2007; status: completed.
02
Drugs
verteporfin
03
Conditions
Age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT00527475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00527475.